Profund Advisors LLC Has $385,000 Position in Kymera Therapeutics, Inc. $KYMR

Profund Advisors LLC lessened its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 29.6% in the second quarter, Holdings Channel.com reports. The fund owned 8,831 shares of the company’s stock after selling 3,718 shares during the quarter. Profund Advisors LLC’s holdings in Kymera Therapeutics were worth $385,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Farther Finance Advisors LLC lifted its stake in shares of Kymera Therapeutics by 642.9% in the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock valued at $27,000 after purchasing an additional 540 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in Kymera Therapeutics in the first quarter valued at about $68,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Kymera Therapeutics by 15.8% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,516 shares of the company’s stock valued at $110,000 after buying an additional 343 shares during the period. Advisors Asset Management Inc. boosted its holdings in Kymera Therapeutics by 81.7% during the first quarter. Advisors Asset Management Inc. now owns 4,959 shares of the company’s stock worth $136,000 after buying an additional 2,230 shares during the last quarter. Finally, AlphaQuest LLC bought a new position in Kymera Therapeutics during the second quarter worth about $222,000.

Insider Transactions at Kymera Therapeutics

In other news, insider Jared Gollob sold 59,576 shares of the business’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $61.42, for a total value of $3,659,157.92. Following the sale, the insider owned 109,992 shares of the company’s stock, valued at $6,755,708.64. The trade was a 35.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Bruce N. Jacobs sold 79,220 shares of the firm’s stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $50.00, for a total transaction of $3,961,000.00. Following the completion of the transaction, the chief financial officer directly owned 227,409 shares of the company’s stock, valued at approximately $11,370,450. This trade represents a 25.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 206,910 shares of company stock worth $11,402,648. Insiders own 16.01% of the company’s stock.

Kymera Therapeutics Trading Up 0.2%

Shares of NASDAQ KYMR opened at $63.63 on Friday. The company has a fifty day moving average price of $55.87 and a 200 day moving average price of $45.97. The firm has a market cap of $4.58 billion, a PE ratio of -17.72 and a beta of 2.32. Kymera Therapeutics, Inc. has a 1-year low of $19.44 and a 1-year high of $65.74.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). The firm had revenue of $2.76 million during the quarter, compared to the consensus estimate of $23.15 million. Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. Equities research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Analysts Set New Price Targets

KYMR has been the topic of a number of analyst reports. Guggenheim began coverage on shares of Kymera Therapeutics in a research report on Monday, November 3rd. They issued a “buy” rating and a $90.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Wednesday, October 8th. Jefferies Financial Group reissued a “buy” rating and issued a $73.00 price target on shares of Kymera Therapeutics in a report on Tuesday, November 4th. B. Riley upped their price objective on shares of Kymera Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, October 24th. Finally, BTIG Research lifted their target price on Kymera Therapeutics from $59.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, October 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $69.75.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.